Contorlled release formulation for the gastroretentive drug delivery system
WO2020242253A1
Novel empagliflozin derivative which is sglt-2 inhibitor
KR20200138055A
Novel Empagliflozin derivatives of SGLT-2 inhibitor
KR102218593B1
Percutaneous Absorption Preparation Comprising Donepezil with Improved Stability
KR102154959B1
Long-acting dual agonists of GLP-1/glucagon receptors
KR20200034648A
A solubilized composition comprising rivaroxaban
KR20200030469A
Pharmaceutical composition for preventing or treating of nonalcoholic fatty liver disease comprising G protein coupled receptor 119 ligand as an active ingredient
Novel salts of Edoxaban and preparation method thereof
KR20200022257A
Process for the preparation of Dapagliflozin prodrug as a SGLT-2 inhibitor
BR112020003319A2
acylated oxintomodulin peptide analog
WO2019035672A1
Acylated oxyntomodulin peptide analog
WO2018155970A1
Novel glucose derivative as sglt-2 inhibitor
KR20180098173A
Novel Glucose derivatives of SGLT-2 inhibitor
KR20190090303A
Novel Salts of Tenofovir alafenamide and methods for Preparing the same
KR20190078893A
Percutaneous Absorption Preparation for Treating Dementia Comprising Donepezil
BR112019012865A2
pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as an effective ingredient for preventing or treating inflammatory bowel disease
KR20190069954A
Sustained-release preparations comprising bepotastine or pharmaceutically acceptable salt thereof
MX2019003585A
Tetrahydropyridine derivatives and their use as antibacterial agents.
